Orlistat Market – Size, Share, Outlook, and
Opportunity Analysis, 2018 – 2026
Orlistat is a drug designed to treat obesity. Primary function of Orlistat is to prevent absorption
of fat from the diet consumed by humans. It prevents absorption of fats by acting as lipase
inhibitors, which eventually reduce the calorie intake. Orlistat works by inhibiting pancreatic
and gastric lipases, pancreatic and gastric enzymes breakdown triglycerides in the intestine.
When activity of lipase is blocked, triglycerides from the diet are not hydrolyzed into
absorbable-free fatty acids, instead remain unchanged. Orlistat also helps in reducing blood
pressure and prevents the onset of type 2 diabetes in obese people. Orlistat medication does not
allow one to regain lost weight and does not block the absorption of fats from non-fat foods
and sugar.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1878
Orlistat Market drivers:-
Increasing number of awareness campaigns for weight management is expected to be a major
driver for Orlistat market growth. For instance, in 2013, Roche Holding AG, a pharmaceutical
company, launched its new campaign ‘New You Weight Consciousness Advocacy Campaign’,
with an aim to increase awareness among the populace regarding obesity and its treatment
options. Such awareness campaigns is expected increase the adoption of weight management
medication treatments, which in turn, is expected to boost growth of the Orlistat market size.
Re-launch of Orlistat products is expected to drive the market growth. For instance, in February
2018, H2 Pharma, LLC. partnered with Cheplapharma Arzneimittel GmbH and re-launched
Xenical Capsules, which was acquired from F.Hoffman-La Roche. Xenical capsules were re-
launched to increase awareness regarding medication related to weight management, this in
turn, is expected to boost orlistat market growth.
Robust pipeline is expected to boost the market growth over the forecast period. For instance,
orlistat by University of Texas South Western Medical center is in phase 2 since 2015. Orlistat
is used for the treatment of hyperlipoproteinemia type 1. Hyperlipoproteinemia type 1 is caused